Movement Alert｜Teva Pharmaceutical Rises 5.15% in Pre-Market Trading, Q2 Revenue Beats Expectations Despite Significant EPS Miss

Market Focus

07/29

On July 29, Teva Pharmaceutical rose 5.15% in pre-market trading, trading at $33.3/share, with turnover of $856,100.

The movement was primarily driven by the company's Q2 earnings release. Teva reported quarterly revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. However, adjusted earnings per share came in at just $0.02, missing the consensus estimate of $0.25 by 92% and representing a nearly 97% decline from $0.66 per share in the year-ago period. Despite the significant EPS shortfall, the top-line beat appears to be supporting pre-market price action.

The company had previously delivered a strong Q1, with adjusted EPS of $0.53 beating the $0.48 estimate by over 10% on revenue of $3.982 billion. Full-year Non-GAAP EPS guidance remains at $1.91 to $2.11. Recent pipeline developments include exclusive rights to commercialize Polpharma's biosimilar candidate to Ocrevus, an NDA submission for ecopipam in pediatric Tourette syndrome, and the European launch of Eylea biosimilar Ahzantive.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1121031859"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121031859\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121031859?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-29 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121031859","market":"us","top_or_hot":-1,"title":"Movement Alert｜Teva Pharmaceutical Rises 5.15% in Pre-Market Trading, Q2 Revenue Beats Expectations Despite Significant EPS Miss","media":"Market Focus","content":"<p><p>On July 29, Teva Pharmaceutical rose 5.15% in pre-market trading, trading at $33.3/share, with turnover of $856,100.</p><p>The movement was primarily driven by the company's Q2 earnings release. Teva reported quarterly revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. However, adjusted earnings per share came in at just $0.02, missing the consensus estimate of $0.25 by 92% and representing a nearly 97% decline from $0.66 per share in the year-ago period. Despite the significant EPS shortfall, the top-line beat appears to be supporting pre-market price action.</p><p>The company had previously delivered a strong Q1, with adjusted EPS of $0.53 beating the $0.48 estimate by over 10% on revenue of $3.982 billion. Full-year Non-GAAP EPS guidance remains at $1.91 to $2.11. Recent pipeline developments include exclusive rights to commercialize Polpharma's biosimilar candidate to Ocrevus, an NDA submission for ecopipam in pediatric Tourette syndrome, and the European launch of Eylea biosimilar Ahzantive.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Teva Pharmaceutical Rises 5.15% in Pre-Market Trading, Q2 Revenue Beats Expectations Despite Significant EPS Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Teva Pharmaceutical Rises 5.15% in Pre-Market Trading, Q2 Revenue Beats Expectations Despite Significant EPS Miss\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time smaller\">2026-07-29 19:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p>On July 29, Teva Pharmaceutical rose 5.15% in pre-market trading, trading at $33.3/share, with turnover of $856,100.</p><p>The movement was primarily driven by the company's Q2 earnings release. Teva reported quarterly revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. However, adjusted earnings per share came in at just $0.02, missing the consensus estimate of $0.25 by 92% and representing a nearly 97% decline from $0.66 per share in the year-ago period. Despite the significant EPS shortfall, the top-line beat appears to be supporting pre-market price action.</p><p>The company had previously delivered a strong Q1, with adjusted EPS of $0.53 beating the $0.48 estimate by over 10% on revenue of $3.982 billion. Full-year Non-GAAP EPS guidance remains at $1.91 to $2.11. Recent pipeline developments include exclusive rights to commercialize Polpharma's biosimilar candidate to Ocrevus, an NDA submission for ecopipam in pediatric Tourette syndrome, and the European launch of Eylea biosimilar Ahzantive.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦製藥","start_time":0,"source_url":"","article_id":"1121031859","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121031859","pubTimestamp":1785323408,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 29, Teva Pharmaceutical rose 5.15% in pre-market trading, trading at $33.3/share, with turnover of $856,100.The movement was primarily driven by the company's Q2 earnings release. Teva...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"走势提醒|梯瓦制药盘前交易上涨 5.15%，尽管每股收益大幅下滑，第二季度收入仍超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"On July 29, Teva Pharmaceutical rose 5.15% in pre-market trading, trading at $33.3/share, with turnover of $856,100.The movement was primarily driven by the company's Q2 earnings release. Teva reported quarterly revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. However, adjusted earnings per share came in at just $0.02, missing the consensus estimate of $0.25 by 92% and representing a nearly 97% decline from $0.66 per share in the year-ago period. Despite the significant EPS shortfall, the top-line beat appears to be supporting pre-market price action.The company had previously delivered a strong Q1, with adjusted EPS of $0.53 beating the $0.48 estimate by over 10% on revenue of $3.982 billion. Full-year Non-GAAP EPS guidance remains at $1.91 to $2.11. Recent pipeline developments include exclusive rights to commercialize Polpharma's biosimilar candidate to Ocrevus, an NDA submission for ecopipam in pediatric Tourette syndrome, and the European launch of Eylea biosimilar Ahzantive.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}